Andy Moye, CEO: AI a Tool for Medicine to help Make Diagnosis More Accurate

Profiles in Leadership

Andy Moye is a seasoned commercial leader and corporate development executive who has worked across the molecular diagnostics, biotechnology and life sciences industries. He is currently Chief Executive Officer at Paige and previously served as Chief Commercial Officer, where he led the company’s clinical sales and commercial strategy, including the U.S. launch of Paige Prostate, the first and only AI-based pathology product to receive FDA approval for in vitro diagnostic (IVD) use in detecting cancer in prostate biopsies.

Previously, Moye served as Head of Commercial Operations in North America and Latin America for the Digital and Computational Pathology division of Philips, delivering significant growth in both markets for the emerging business. Moye has also served in executive roles at leading healthcare companies, including Ontada, a division of McKesson, Caris Life Sciences, and WaferGen Bio-systems, now part of Takara Bio. Prior to joining the industry, Moye served as a Lieutenant and flight officer in the U.S. Navy, completing missions in Bosnia, Kosovo, Iraq, Europe, and South America. He received a Ph.D. in health economics from Walden University, MBA from the University of Florida and B.S. in physiology from the University of Arizona.